Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
World J Surg Oncol. 2009 Apr 8;7:38. doi: 10.1186/1477-7819-7-38.

Treatment of early uterine sarcomas: disentangling adjuvant modalities.

Author information

  • 1Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, School of Medicine, Athens, Greece. florazagouri@yahoo.co.uk

Abstract

Uterine sarcomas are a rare group of neoplasms with aggressive clinical course and poor prognosis. They are classified into four main histological subtypes in order of decreasing incidence: carcinosarcomas, leiomyosarcomas, endometrial stromal sarcomas and "other" sarcomas. The pathological subtype demands a tailored approach. Surgical resection is regarded as the mainstay of treatment. Total abdominal hysterectomy and bilateral salpingo-oophorectomy represents the standard treatment of uterine sarcomas. Pelvic and para-aortic lymph node dissection in carcinosarcomas is recommended, given their high incidence of lymph node metastases, and may have a role in endometrial stromal sarcomas. Adjuvant radiation therapy has historically been of little survival value, but it appears to improve local control and may delay recurrence. Regarding adjuvant chemotherapy, there is little evidence in the literature supporting its use except for carcinosarcomas. However, more trials are needed to address these issues, especially, their sequential application. Patients with uterine sarcomas should be referred to large academic centers for participation in clinical trials.

PMID:
19356236
[PubMed - indexed for MEDLINE]
PMCID:
PMC2674046
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk